<DOC>
	<DOCNO>NCT00154284</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy everolimus combination basiliximab , steroid without cyclosporine microemulsion de novo kidney transplant recipient .</brief_summary>
	<brief_title>Everolimus Cyclosporine Microemulsion-free Regimen Compared Low-dose Cyclosporine Microemulsion Regimen , de Novo Kidney Transplant Patients</brief_title>
	<detailed_description>This combined analysis use 81 patient randomize treated CRAD001A2419 ( NCT00154284 ) 33 randomize treat CRAD001A2423 ( NCT00170807 ) . This approach reflect protocol amendment study , one clinical study report .</detailed_description>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Recipients first renal transplant primary cadaveric nonHLA identical living relate donor . Renal cold ischemic time &lt; 36 hour . Age donor &lt; 65 year . Patients receive investigational drug within 4 week baseline period . Patients recipients multiple organ transplant , include organ kidney . Recipients nonheart beat donor organ . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Renal transplantation ,</keyword>
	<keyword>everolimus ,</keyword>
	<keyword>immunosuppressant ,</keyword>
	<keyword>basiliximab ,</keyword>
	<keyword>cyclosporine microemulsion discontinuation , cyclosporine microemulsion minimization</keyword>
</DOC>